Sanofi

Company

Company Profile

Sanofi is a French multinational pharmaceutical and healthcare company headquartered in Paris. The company was established in 1973 and now trades on Euronext Paris and Nasdaq.

Website: https://www.sanofi.com
Headquarters: Paris, France
Founded: 1973
Stock Ticker: NASDAQ:SNY

Related News

Three Manufacturers Supply 90% of Global Insulin as Biosimilars Erode Oligopoly

Jun 28, 2026

The global insulin drugs and delivery devices market is dominated by three manufacturers supplying roughly 90% of volume, with biosimilar entry slowly eroding this oligopoly. The market is projected to see continued growth driven by rising diabetes prevalence, while pricing pressure from biosimilars and government policies accelerates. In the Middle East, the recombinant human insulin market is projected to expand at a 6–8% CAGR through 2035.

Sanofi Announces Leadership Transition and Key Regulatory Updates Amid Pipeline Advancements

Jun 25, 2026

Sanofi announces leadership transition with CEO departure and interim appointment, while reporting key regulatory milestones including FDA Breakthrough Therapy designation for venglustat and expanded Dupixent approvals. The company advances an observational RSV study in Australia and outlines strategic initiatives in AI drug discovery and potential consumer healthcare spin-off.

Teva and Sanofi's Duvakitug Shows Durable Efficacy in UC and Crohn's Disease Phase 2b Data

Jun 13, 2026

Teva Pharmaceuticals and Sanofi reported positive Phase 2b long-term extension results for duvakitug, a TL1A-targeting monoclonal antibody, showing durable efficacy over 44 weeks in ulcerative colitis and Crohn's disease patients. UC patients achieved up to 58% clinical remission and CD patients up to 55% endoscopic response at the higher dose.

Pharmaceutical Market Forecasts: Respiratory, Fibrosis, and Digital Health Segments Project Growth

Jun 06, 2026

Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.

FAERS Analyses Uncover Diverse Drug Safety Risks Across Therapeutic Areas

Jun 02, 2026

Recent studies using FDA Adverse Event Reporting System data have identified drug-associated cardiovascular risks, pediatric dry eye, and venlafaxine adverse effects. Findings highlight the importance of pharmacovigilance monitoring.

Nurix Highlights Oncology and Immunology Degrader Pipeline Progress

May 18, 2026

Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.

Insulin costs and PBM scrutiny intensify pressure on drug affordability

May 10, 2026

Insulin list prices rose more than 300% over two decades as PBMs face growing scrutiny over rebates, spread pricing, and transparency. Reform efforts and pharmacist involvement are central to drug affordability and access.

Biosimilar and biologic updates include approvals, review decisions and licensing deals

Apr 29, 2026

Recent biosimilar and biologic developments included Health Canada approval of denosumab biosimilars, FDA review actions, and new licensing and commercialisation agreements. Other updates covered court, trial and reimbursement agenda decisions.

Novartis' Rhapsido Gets EU Approval for CSU, Shows Promise in CINDU Phase 3 Trial

Apr 28, 2026

Novartis received EU approval for Rhapsido (remibrutinib) as the first oral targeted treatment for chronic spontaneous urticaria. Phase 3 data also showed significant efficacy in chronic inducible urticaria, with filings underway for additional indications.

EU panel backs Sanofi’s tolebrutinib for secondary progressive multiple sclerosis

Apr 24, 2026

The EMA’s CHMP recommended approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing secondary progressive multiple sclerosis. The phase 3 HERCULES study showed reduced disability progression, while liver injury remains an identified safety risk.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07615192	RSV Immunisation Status in Queensland (Australia)	NOT_YET_RECRUITING
NCT07615179	Alirocumab and Ischemic Risk in Atherosclerotic Cardiovascular Disease (ASCVD)	ACTIVE_NOT_RECRUITING
NCT07615166	Low-Density Lipoprotein Cholesterol Reduction With Alirocumab 150 mg Versus Inclisiran in Individuals Initiating Therapy in Routine Clinical Practice	ACTIVE_NOT_RECRUITING
NCT07612878	The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry	NOT_YET_RECRUITING
NCT07612475	Type 1 Diabetes Screening	NOT_YET_RECRUITING
NCT07606508	Follow-up of a French National Cohort of Patients With Cutaneous Squamous Cell Carcinoma Requiring Systemic Treatment.	RECRUITING
NCT07600151	Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07587658	This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization	NOT_YET_RECRUITING	PHASE4
NCT07556159	A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice	RECRUITING
NCT07547436	A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis	RECRUITING	PHASE2